The 2019 Annual General Meeting was held on 26 March 2019 in Helsinki. Read more here.
|5/13/2019||Orion Corporation completed share acquisitions|
|5/13/2019||ORION CORPORATION: ACQUISITION OF OWN SHARES 13.05.2019|
|5/10/2019||ORION CORPORATION: ACQUISITION OF OWN SHARES 10.05.2019|
|5/9/2019||ORION CORPORATION: ACQUISITION OF OWN SHARES 09.05.2019|
|4/29/2019||U.S. FDA accepts New Drug Application for review and grants Priority Review for darolutamide|
|4/11/2019||Fire at Orion’s manufacturing plant in Turku|
|4/11/2019||Publishing of Orion Corporation's Interim Report for January-March 2019 on 25 April 2019|
|3/27/2019||Invitation to Orion's Capital Markets Day in Helsinki on Wednesday 22 May 2019|
The product and service portfolio of Orion includes a variety of human pharmaceuticals, veterinary drugs, APIs and contract manufacturing.
Orion’s pharmaceutical innovations are created within its R&D organisation. The organisation employs top professionals in the field of drug molecule development and optimisation.
One key area of Orion's business is Critical Care. Our portfolio includes Simdax® for acute heart failure and Precedex® and Dexdor® for sedation. Read more about Orion's proprietary products and other human pharmaceuticals.
Orion is the largest employer in the Finnish pharmaceutical industry. It is considered to be a good and reliable employer, which is also indicated by its lower-than-average employee turnover.